Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in HumansGreetje J. de Grooth, John J.P. Kastelein, Jan Albert Kuivenhoven et al.|Circulation|2002Cited by 455
Cholesteryl Ester Transfer Protein TaqIB Variant, High-Density Lipoprotein Cholesterol Levels, Cardiovascular Risk, and Efficacy of Pravastatin TreatmentS. Matthijs Boekholdt, J Kastelein, J. Wouter Jukema et al.|Circulation|2005Cited by 310
Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS)Anke H.E.M. Klerkx, John J.P. Kastelein, Greetje J. de Grooth et al.|European Journal of Clinical Investigation|2004Cited by 103
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemiaGreetje J. de Grooth, Jan Albert Kuivenhoven, Tineke J. Smilde et al.|Atherosclerosis|2004Cited by 84